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Multinucleated giant cells (MGCs) are implicated in many diseases including schistoso-
miasis, sarcoidosis and arthritis. MGC generation is energy intensive to enforce membrane
fusion and cytoplasmic expansion. Using receptor activator of nuclear factor kappa-Β ligand
(RANKL) induced osteoclastogenesis to model MGC formation, here we report RANKL
cellular programming requires extracellular arginine. Systemic arginine restriction improves
outcome in multiple murine arthritis models and its removal induces preosteoclast metabolic
quiescence, associated with impaired tricarboxylic acid (TCA) cycle function and metabolite
induction. Effects of arginine deprivation on osteoclastogenesis are independent of mTORC1
activity or global transcriptional and translational inhibition. Arginine scarcity also dampens
generation of IL-4 induced MGCs. Strikingly, in extracellular arginine absence, both cell types
display ﬂexibility as their formation can be restored with select arginine precursors. These
data establish how environmental amino acids control the metabolic fate of polykaryons and
suggest metabolic ways to manipulate MGC-associated pathologies and bone remodelling.
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Exacerbated bone resorption by tissue resident osteoclastsunderlies the pathogenesis of multiple chronic inﬂamma-tory joint diseases, which are signiﬁcant burdens to human
health1. Tartrate-resistant acid phosphatase (TRAP)-positive
multinucleated osteoclast generation from myeloid progenitors
relies on cytokines, most importantly receptor activator of nuclear
factor kappa-Β ligand (RANKL) and macrophage colony stimu-
lating factor (M-CSF)2. However, depending on the tissue, the
transcriptional landscape of resident cells is also dictated by their
surroundings, with changes in extracellular microenvironment
through amino acid (AA) supplementation/restriction regulating
immune cell plasticity3–6. A hallmark of this plasticity is the ﬁne
tuning of cellular metabolism that allows immune cells, especially
macrophages to dynamically adjust their metabolism according to
available extracellular energy sources. Such metabolic ﬂexibility in
response to changing environmental conditions represents an
important paradigm in innate immune cell biology4,6,7. Analo-
gously, cancer cells are able to adjust their metabolism in the face
of nutrient shortage by rewiring their metabolism to efﬁciently
utilize alternative metabolites, thereby sustaining their prolifera-
tion8. Nonetheless, compensation cannot occur for every nutrient
as enzymes that deplete speciﬁc AAs can be utilized to limit
auxotrophic cancer cell growth. For example, L-asparaginase is
used in acute lymphatic leukaemia treatment, but its therapeutic
efﬁcacy is limited by side effects9. Recent clinical studies
employed pegylated recombinant arginase 1 (recArg1 or BCT-
100) to deplete arginine in various cancers, yet impacts of argi-
nine availability on other disease settings remains relatively
unexplored10,11. We reasoned that manipulating environmental
arginine could alter local cellular metabolism within bone, pos-
sibly through impacts on tissue resident osteoclasts and thus
change the trajectory of arthritis-induced bone loss.
To test this hypothesis, we used recArg1 to study the effects of
arginine depletion in arthritis and osteoclastogenesis. RecArg1
exerts beneﬁcial effects in murine arthritis by dampening osteo-
clast metabolism and differentiation. In arginine scarcity, osteo-
clasts and IL-4-induced multinucleated giant cells (MGCs)
display ﬂexibility in their development, as their formation can be
restored by supplementation with select arginine precursors. Our
results highlight the importance of environmental arginine in
MGC development and show therapeutic effects of systemic
extracellular arginine depletion in murine arthritis.
Results
RecArg1 exerts beneﬁcial effects in murine arthritis. To
investigate if systemic arginine manipulation modulated bone
diseases, we ﬁrst used recArg1 in serum transfer arthritis (K/
BxN), which is characterized by RANKL-induced bone erosion
(Supplementary Fig. 1a)12. Arginine depletion during disease
caused improved clinical outcomes as evaluated by increased grip
strength associated with reduced paw swelling (total score) and
weight loss. Histological analysis revealed decreased formation of
osteoclasts in arthritic paws, whereas we found negligible effects
of arginine bioavailability on joint inﬂammation (Fig. 1a). Using a
different arthritis model, we found arginine was equally impor-
tant in tumour necrosis factor (TNF)-dependent arthritis
(hTNFTg/+, Supplementary Fig. 1b)13. Its restriction improved
clinical disease parameters, independent of weight, and led to
decreased formation of bone resorbing osteoclasts, suggesting a
predominant effect of recArg1 treatment on osteoclast formation
in arthritis (Fig. 1b). Finally, we systemically depleted arginine in
collagen-induced arthritis (CIA), a model also dependent on
adaptive immunity (Supplementary Fig. 1c)14. In vivo imaging
revealed attenuated osteoclast-speciﬁc paw cathepsin K (Ctsk)
amounts during arginine restriction, accompanied by decreased
clinical scores, unconnected from weight gain (Fig. 1c). Local
Ctsk, Acp5 and Tnf transcripts increased in paws of ill versus
healthy animals, conﬁrming that the disease was linked to ele-
vated osteoclastogenesis and inﬂammation. Although arginine
depletion decreased Ctsk and Acp5 mRNA expression, no effects
were observed on Tnf mRNA, indicating that arginine depletion
had a preferential effect on the transcriptional program of
osteoclastogenesis rather than a global effect on inﬂammation
(Supplementary Fig. 1d). Concordantly, while a secondary col-
lagen challenge ex vivo induced robust splenocyte proliferation in
diseased versus healthy animals, we detected no difference in
recArg1-treated versus sham-treated arthritic animals (Supple-
mentary Fig. 1e). Systemic arginine amounts in healthy animals
were 200–300 µM, slightly above adult humans15 and as expected,
depleted by recArg1 during disease (Fig. 1d). This was associated
with increases in ornithine and other AAs (Supplementary
Fig. 1f). Of note, in CIA, myeloid populations including osteoclast
precursors were unaffected by arginine restriction, as was the
systemic RANKL/OPG ratio in all models studied (Supplemen-
tary Fig. 1g–i), suggesting that decreased osteoclast numbers
found in arthritis were due to differentiation of osteoclasts. Col-
lectively, we concluded that recArg1 exerts beneﬁcial effects in
murine arthritis, likely by dampening osteoclastogenesis.
To validate a potential cross-talk between the arginine pathway
and bone degrading osteoclasts in patients suffering from
rheumatoid arthritis (RA), we evaluated patients with respect to
their osteoclast activity, grouping them into those suffering from
erosive and non-erosive RA. Serum crosslaps, collagen degrada-
tion fragments produced from bone resorbing osteoclasts,
conﬁrmed their enhanced activity in erosive versus non-erosive
patients (Fig. 1e). Versus healthy controls, arginine serum
amounts exhibited a tendency to be enhanced in humans with
erosive RA (Fig. 1f). In these patients, arginase 1 (ARG1) was
signiﬁcantly increased versus non-erosive patients and positively
correlated with patient erosion scores (Fig. 1g). Together these
data suggest of a physiological role of ARG1 in limiting osteoclast
activity by arginine removal and illustrate an importance of the
arginine pathway as well for human bone degradation in RA.
Extracellular arginine removal attenuates osteoclastogenesis.
To investigate the molecular and cellular mechanisms associated
with arginine restriction in bone disease, we next dissected
osteoclastogenesis induced with M-CSF/RANKL in the presence
or absence of recArg1 using different systems-type approaches.
For simplicity, we refer to M-CSF+ RANKL treatment as
RANKL and M-CSF+ RANKL+ recArg1 treatment as recArg1,
unless otherwise indicated (Fig. 2a). The control RANKL tran-
scriptome consisted of 464 mRNA expression changes with 249
being down- and 215 upregulated. As expected, the latter inclu-
ded hallmark osteoclastic genes; Fos, Nfatc1, Acp5 and Jdp216 and
KEGG analysis showed enrichment for osteoclast differentiation
(Supplementary Fig. 2a, b). At the mRNA level, perturbations in
arginine biosynthesis and arginine and proline metabolism sug-
gested an osteoclast-dependent importance for arginine metabo-
lism (Fig. 2b). Indeed, recArg1 completely blocked murine
osteoclastogenesis, an effect abolished by enzyme denaturation
and independent of effects on cell viability and also inhibited
human osteoclastogenesis (Fig. 2c–f). Treatment with recArg1
affected RANKL-induced gene expression already after 24 h,
preceding RANKL effects on osteoclast fusion that mainly
occurred at 72–96 h (Fig. 2e, Supplementary Figs. 2c and 3a),
indicating recArg1 affects osteoclastogenesis by selectively redu-
cing RANKL-dependent gene expression. These data suggest an
important link between RANKL signalling and arginine meta-
bolism and that depletion of extracellular arginine upon recArg1
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treatment results in dynamic transcriptional changes that
attenuate osteoclastogenesis.
To evaluate the importance of intracellular arginine degrada-
tion by cellular ARG1 during RANKL-induced osteoclast
differentiation, we used the Tie2-cre system to selectively delete
Arg1 in hematopoietic osteoclast precursors17. Deﬁciency of
cellular ARG1 within myeloid precursors did not affect osteoclast
differentiation, indicating environmental decreases in extracellu-
lar arginine mediated by recArg1 exhibit distinct functions with
respect to osteoclast differentiation versus those mediated by
cellular ARG1 (Fig. 2g–h). Underscoring the negligible effects
observed of conditional Arg1 deletion on osteoclastogenesis, we
observed persistent downregulation of Arg1 transcript and
protein levels post RANKL treatment during osteoclastogenesis
of wildtype preosteoclasts (Fig. 2h–i, Supplementary Fig. 2a). To
further test the speciﬁcity of extracellular arginine in RANKL
signalling and osteoclastogenesis, we next treated innate immune
cells with recArg1 during their differentiation in an identical
manner to osteoclasts. RecArg1 exerted minor inﬂuences on
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Fig. 1 Recombinant arginase 1 (recArg1) improves outcome in diverse murine arthritis models and arginase 1 is elevated in erosive RA patients.
a, b Paw histology, osteoclast numbers per hind paw (N. Oc), total scores, weight and histology inﬂammation area of mice suffering from serum transfer
arthritis (a K/BxN, NaCl n= 12, recArg1 n= 13 animals) or the hTNFtg/+ mouse model (b NaCl n= 13, recArg1 n= 14 animals). Scale bar represents 1 mm.
c Ctsk IVIS and quantiﬁcation, total scores and weights of mice suffering from collagen-induced arthritis (CIA, NaCl n= 13, recArg1 n= 14 animals, Ctsk
IVIS n= 6 animals). d RecArg1 depletes serum arginine; K/BxN (n= 13 animals per group), CIA (NaCl n= 13, recArg1 n= 14 animals). NaCl in
a–d represents saline vehicle control group. e Serum crosslaps in the indicated patient groups (erosive RA n= 30, non-erosive RA n= 29 patients). f Serum
arginine levels of all patient groups (healthy n= 19, erosive RA n= 29, non-erosive RA n= 30 patients). g Arginase 1 levels in all patient groups and
correlation between arginase 1 and erosion score of patients suffering from erosive RA (healthy n= 19, erosive RA n= 29, non-erosive RA n= 30 patients).
Data are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, unpaired t-test (a–c, e–g), one-way ANOVA (d) and two-way ANOVA post-hoc
pairwise comparisons with Bonferroni correction (a–c), linear regression (g). Source data are provided as a Source Data ﬁle.
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Fig. 4), suggesting differential environmental arginine require-
ments for M-CSF/GM-CSF versus RANKL signalling, the latter of
which is well described to be important for multinucleated
osteoclast formation.
RecArg1 counteracts RANKL cellular programmes. Up to now,
we utilized exogenous recArg1 to deplete extracellular arginine to
block osteoclastogenesis. We next determined the relative con-
tributions of selective arginine depletion versus other potential
effects of recArg1 including ornithine and urea generation, which
are the products of the arginase reaction6. We compared pre-
osteoclasts treated with RANKL (RANKL) versus recArg1
(RANKL/Arg-Depletion) or cultured in Arg-Free media (RANKL/
Arg-Starvation). As controls, we re-supplemented arginine into
Arg-Free media (RANKL/Arg-Rescue) and included M-CSF-treated
preosteoclasts (M-CSF) starved of arginine (M-CSF/Arg-Starvation)
(Fig. 3a). Plotting similarity between transcriptomic samples using
multi-dimensional scaling (MDS), we found Arg-Starvation altered
RANKL-induced effects, while the M-CSF transcriptome was
minimally affected, conﬁrming arginine requirements for RANKL
signalling. RANKL/Arg-Depletion demonstrated more pronounced
segregation from RANKL than RANKL/Arg-Starvation samples,
whilst both proﬁles were distinct from M-CSF conditions (Fig. 3b
and Supplementary Fig. 5a). Nonetheless, when we plotted
RANKL-dependent gene expression in Arg-Depleted versus Arg-
Starved cells, we observed highly correlated signatures (Fig. 3c).
While recArg1 had the strongest effect on the RANKL tran-
scriptome, most genes (119) signiﬁcantly modiﬁed by Arg-
Starvation (150) were shared with Arg-Depletion (420), although
genes speciﬁc for both were identiﬁed (Supplementary Fig. 5b).
Thus, we concluded that recArg1 largely acts on RANKL-induced
MGC generation via arginine depletion, rather than via the pro-
ducts of the Arg1 reaction.
To dissect the cellular and metabolic changes caused by
arginine restriction during osteoclast development, we next
used a proteomic approach to probe whether Arg-Depletion in
preosteoclasts caused an altered proteome (Fig. 3a, Supplemen-
tary Fig. 5c). We did not observe a global translational decrease
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Fig. 2 Extracellular arginine is essential for RANKL-induced osteoclastogenesis. a Schematic of systems-wide approaches performed to understand the
effect of recArg1 on RANKL dependent osteoclastogenesis. b KEGG metabolic enrichment of differentially expressed genes upon RANKL treatment.
c Representative TRAP stainings depicting that recArg1 abolishes murine and human RANKL-induced osteoclastogenesis. d Quantiﬁcation of murine data
depicted in c (n= 6). e qRT-PCR time course of Nfatc1 and Fos (n= 3). f Quantiﬁcation of viable cells 24 h post RANKL/recArg1 treatment (n= 4).
g, h Osteoclastogenesis is unchanged by Arg1 deﬁciency. TRAP stainings (g) and Western blots of ARG1 in preosteoclasts (Pre-OC) and osteoclasts (OC)
(h). i qRT-PCR time course of Arg1 (n= 3). Data are mean ± SEM, *P < 0.05, ***P < 0.001, ****P < 0.0001, one-way ANOVA (d) and two-way ANOVA
post-hoc pairwise comparisons with Bonferroni correction (e). Scale bar represents 200 µm (c, g). Source data are provided as a Source Data ﬁle.
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proteins were induced under low arginine conditions (Fig. 3d,
Supplementary Fig. 5d). RANKL addition controlled expression
of 349 out of 512 identiﬁed proteins with increases/decreases in
171/178 proteins, respectively (Fig. 3e). Only 43 RANKL-
induced proteins were counteracted by recArg1 treatment,
including those associated with osteoclastogenesis as we
expected, as well as proteins involved in the actin cytoskeleton,
DNA replication and the cell cycle (Fig. 3f). Thus, as found for
the transcriptome, Arg-Depletion had a selective effect on
proteins regulated by the RANKL pathway. Examining cell
cycle status revealed that while arginine was required for
RANKL-induced G2/M cell cycle progression that preceded cell
fusion, its withdrawal was equivalent to M-CSF- treated cells,
suggesting diminished cellular proliferation (Supplementary
Fig. 3a, b). Importantly, although arginine depletion through
recArg1 modulated unique proteins, many mediated similar
biological processes to the RANKL signature (Fig. 3f). Taken
together, these data allowed us to conclude that RANKL cellular
programming relies on extracellular arginine, as recArg1 largely
counteracted the RANKL-dependent transcriptome and
proteome.
Osteoclast oxidative metabolism is arginine dependent. Argi-
nine withdrawal has often been associated with inhibition of
mTORC1 signalling, a key regulator of cellular proliferation and
translation18. Concordant with minor effects of arginine depri-
vation on preosteoclast translation, M-CSF/RANKL mediated
mTOR phosphorylation and activation of downstream signalling
pathways (pS6K, 4E-BP1) but was largely unaltered by recArg1
(Fig. 4a). In addition, genetic deletion of mTOR signalling com-
ponents, Tsc2 and Rictor19, an arginine sensor important for
mTORC1 responses (Slc38a9)18,20 or components of the inte-
grated stress response including the known AA sensor GCN2
(Eif2ak4) and one of its downstream transcriptional mediators
(Ddit3)21, could not bypass the effects of arginine withdrawal on
osteoclastogenesis (Fig. 4b).
Having excluded roles of key arginine sensing pathways, we
next probed the effect of arginine on osteoclast metabolism.
Integrative network analysis of arginine effects on the RANKL
signature, unifying transcriptomic and proteomic data, suggested
that oxidative metabolism represented an important metabolic
hub linked to arginine presence (Supplementary Fig. 6a and
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Fig. 3 Arginine presence speciﬁcally sustains RANKL gene and protein expression. a Workﬂow dissecting recArg1 speciﬁcity on RANKL signalling. Arg-
sufﬁcient (pink) and Arg-deﬁcient (grey) conditions in arginine sufﬁcient (aMEM) or deﬁcient media (Arg-Free) depicted. b MDS of transcriptomic
datasets in a, keeping all genes expressed in at least three of the samples. c Linear regression of average gene expression (n= 4) for RANKL/Arg-
Depletion against RANKL/Arg-Starvation. d Heatmap of proteomics data in a, showing Z-score of abundance level per protein across all conditions
(RANKL-conditions shown only, full heatmap in Supplementary Fig. 5d). e Volcano plot showing difference between M-CSF/Arg-Rescue versus RANKL/
Arg-Rescue (n= 4). Highlighted are proteins modulated by RANKL in an arginine-dependent manner. f Volcano plot showing difference between RANKL/
Arg-Rescue versus RANKL/Arg-Depletion (n= 4). Highlighted are proteins uniquely inﬂuenced by recArg1.
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bursts in preosteoclast spare respiratory capacity at 48 h post
stimulation, as previously described22. These RANKL-mediated
increases were counteracted by recArg1, in a manner that was
independent of changes in mitochondrial mass (Fig. 4c and
Supplementary Fig. 7a, b)23. Moreover, versus the M-CSF control,
RANKL markedly induced preosteoclast glycolytic rates, inde-
pendent of changes in glucose uptake (Fig. 4d, e). Elevated
preosteoclast glycolysis under RANKL treatment was indepen-
dent of arginine as no decrease was observed with recArg1
addition (M-CSF+RANKL+recArg1) (Fig. 4d, e). Using a
metabolomic approach, we observed RANKL-dependent induc-
tion of key intracellular tricarboxylic acid (TCA) cycle
intermediates (e.g. malate, fumarate, succinate, α-ketoglutarate)
24 h post stimulation and only subtle changes in intracellular AAs
(e.g. arginine, glycine, alanine) (Fig. 4f, Supplementary Fig. 7c).
Oxygen consumption rates (OCRs) 24 h post RANKL treatment
were unchanged compared to M-CSF, indicating that RANKL-
induced changes in TCA metabolites preceded the observed boost
in OXPHOS (Supplementary Fig. 7e).
Arginine is an integral part of the urea cycle, which is connected
to the TCA cycle via a shunt through fumarate, linking both
cycles24. RANKL-induced TCA metabolites were in agreement with
robust TCA cycle enzymatic transcription, e.g. those converting














































































































































































































































































































































































































































































Fig. 4 Dynamic changes in metabolism to decreased extracellular arginine during RANKL-dependent osteoclastogenesis occur mTOR independently. a
RecArg1 exerts negligible effects on RANKL-mediated mTOR-related pathways. b Deﬁciency in mTOR/AA-starvation components cannot rescue effects of
Arg-Depletion. Scale bar represents 200 µm. c–e Oxygen consumption rate (OCR), spare respiratory capacity (SRC) and basal glycolytic rate (ECAR) of
preosteoclasts ± recArg1 (c, d n= 8). Negligible effects of arginine deprivation on preosteoclast 2-NBDG (glucose) uptake (e n= 4). All data 48 h post
stimulation. f RANKL differentially changed metabolites intra-/extracellularly ± recArg1. Data normalized against M-CSF (left) and represent mean (n= 4,
RANKL intracellular n= 3; see Supplementary Fig. 7c, d) g Transcriptional proﬁles of selected KEGG pathways. TCA cycle and serine/purine biosynthetic
enzymes indicated. Data represent mean (n= 4). Signiﬁcance levels according to empirical permutation test, empirical P-values reported. Data are mean ±
SEM, *P < 0.05, ****P < 0.0001, one-way ANOVA post-hoc pairwise comparisons with Bonferroni correction (c–e) and two-way ANOVA post Sidak’s
multiple comparisons test (c). Source data are provided as a Source Data ﬁle.
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and fumarate to malate (Fh1)24 (Fig. 4g). RecArg1 further led to
extracellular arginine depletion via conversion to ornithine and urea
and reversed the intracellular build-up of malate, fumarate,
succinate and α-ketoglutarate induced by RANKL (Fig. 4f and
Supplementary Fig. 7c, d), suggesting arginine depletion was linked
to a rewired TCA cycle. Indeed, recArg1 counteracted speciﬁc
RANKL-induced TCA enzyme expression, while upregulating
serine and purine biosynthetic enzymes (Pck2, Eno2, Phgdh)
(Fig. 4g, Supplementary Fig. 2f)8. Consistent with the notion of
diverted biosynthetic ﬂuxes upon arginine depletion, increased
expression of the pyruvate anabolic genes Glud1 and Gpt2 occurred
(Supplementary Fig. 2d). Collectively, our data show that
extracellular arginine is required for successful RANKL-dependent
TCA cycle upregulation and consecutive increases in oxidative
phosphorylation. Our data further suggest that either arginine
turnover impacts the TCA cycle, or that the increases in OXPHOS
by RANKL are linked to arginine-dependent transcription of TCA
cycle enzymes and related metabolite induction or a combination
of both.
RecArg1 instigates a dysregulated TCA cycle in osteoclasts. To
distinguish between the possibilities noted above, we next
performed 13C-isotopologue labelling experiments. As the carbon
backbone of arginine cannot serve as a direct source for TCA
cycle intermediates25, we supplied 13C6 arginine in combination
with 13C4 aspartate in the ﬁrst 24 h of osteoclastogenesis and
measured intracellular isotopologue distribution via liquid
chromatography–mass spectrometry (LC–MS) analysis. In this
way, we could assess the contribution of each carbon source to
both the urea and the TCA cycle simultaneously, as aspartate can
be readily converted through argininosuccinate into fumarate via
the TCA-Urea cycle shunt (Fig. 5a). 13C6 arginine was readily
taken up by both M-CSF- and RANKL-treated cells, as we
detected 100–200 times more intracellular labelled arginine in
relation to unlabelled arginine. In line with negligible increases in
arginine transporter transcription (Slc7a1, Slc7a2) (Supplemen-
tary Fig. 2e)26, we observed no difference in 13C6-labelled argi-
nine uptake upon RANKL treatment post 24 h. Both M-CSF and
RANKL treated cells engaged in arginine recycling as indicated by
m+ 5 labelling in both citrulline and arginine (Fig. 5b). Notably,
as arginine was readily converted to ornithine and urea by
recArg1 in the supernatant, we could barely detect labelled
intracellular 13C6 arginine upon recArg1 treatment (Figs. 4f, 5b,



























































































































































































































































































































































Fig. 5 Metabolic tracing of arginine and aspartate reveal arginine withdrawal instigates a dysregulated TCA cycle. a Schematic of the fate of the 13C-
labelled atoms deriving from arginine (pink) or aspartate (turquoise). b Ratio of intracellular 13C6-labelled arginine to unlabelled 12C6 arginine pool and
percent m+ 5 citrulline and m+ 5 arginine normalized to the labelled 13C6 arginine pool (n= 4). c Intracellular m+ 5 ornithine, m+ 4 putrescine and m+
4 spermidine normalized to 13C6-labelled arginine input (n= 4). d Excess of recArg1 degradation products ornithine and urea do not impact
osteoclastogenesis (n= 6). e Effect of extracellular polyamines and polyamine synthesis inhibitor diﬂuoromethylornithine (DFMO) on osteoclastogenesis
(n= 4). f Intracellular m+ 4 fumarate and m+ 4 malate normalized to 13C4-labelled aspartate input (n= 4). Data are mean ± SEM, *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001, one-way ANOVA post-hoc pairwise comparisons with Bonferroni correction (b–f). Source data are provided as a Source
Data ﬁle.
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intracellular 13C6 arginine, under arginine depletion, we detected
high quantities of 13C5-labelled ornithine and its downstream
metabolites putrescine and spermidine, because the enhanced
ornithine generated by recArg1 was further catabolized to form
polyamines and came from the extracellular 13C6 arginine sup-
plied (Fig. 5c). Suggestive of uptake and/or synthesis from m+ 5
ornithine occurring under 13C labelling, total intracellular
amounts of the polyamines putrescine and spermidine were
decreased upon recArg1 treatment in comparison to RANKL
(Figs. 4f, 5c, Supplementary Fig. 7c). RNA sequencing analysis
demonstrated that similar to macrophages, ornithine transcar-
bamylase (OTC) was not expressed in preosteoclasts27 (see
deposited data), therefore ornithine cannot be converted to
citrulline in these cells. Together, these data indicate that recArg1
treatment converts all extracellular arginine to ornithine and the
polyamines as demonstrated by the lack of m+ 5 citrulline and
m+ 5 arginine (Fig. 5b, c).
Excess of extracellular ornithine and urea did not have any
consequences on osteoclastogenesis, proving that the recArg1-
instigated blocks in osteoclastogenesis were not due to increases
in these metabolites (Fig. 5d). It was previously shown that
extracellular polyamines negatively regulate osteoclastogenesis28.
However, although recArg1 led to a shift in putrescine and
spermidine amounts, their addition at excess (500 µM putrescine
and 10 µM spermidine) during osteoclastogenesis caused an
approximately 30 and 75% decrease in TRAP-positive cells,
respectively. Thus, although accumulation of polyamines upon
recArg1 might negatively impact osteoclastogenesis, their
increased synthesis cannot fully account for the complete absence
of TRAP-positive cells observed under arginine deprivation
(Fig. 5e). As we wanted to test if inhibitory effects of recArg1
treatment on osteoclastogenesis were mediated by decreased
intracellular polyamine synthesis (Fig. 4f, Supplementary Fig. 7c),
we incubated cells with alpha-diﬂuoromethylornithine (DFMO),
thereby blocking conversion of ornithine to putrescine29. Despite
DFMO reducing osteoclastogenesis, multinucleated mature
osteoclasts were still observed (Fig. 5e). Overall, these data
suggest an importance for polyamines in the context of
osteoclastogenesis. However, the effects of recArg1 cannot be
solely accounted by deregulated polyamine metabolism.
To prove an operating urea–TCA cycle shunt in preosteoclasts,
we simultaneously performed a 13C4 aspartate tracing. Suggesting
the aspartate–argininosuccinate–fumarate shunt functioned in
preosteoclasts independent of arginine presence, we observed
equal m+ 4 fumarate labelling in all conditions (Fig. 5f). Notably,
as fumarate was m+ 4 labelled, we concluded the carbon source
stemmed from argininosuccinate, as direct conversion from
aspartate to oxaloacetate would have yielded m+ 2 fumarate
(Fig. 5a). Consistent with arginine deprivation globally down-
regulating TCA cycle enzymes (Fig. 4g), we observed higher
abundance of m+ 4 malate relative to 13C4 aspartate input
following recArg1 treatment compared to M-CSF and RANKL
control conditions (Fig. 5f). Although arginine and its catabolic
products cannot directly enter the TCA cycle, the metabolic
tracing data utilizing fully labelled aspartate strengthen the notion
that arginine presence is required for a functioning TCA cycle.
AA precursors compensate for AA absence in osteoclastogen-
esis. So far we showed that the arginine-dependent dysregulated
TCA cycle-initiated cell cycle arrest was not associated with
known properties of quiescence including decreased glycolysis,
reduced translation rates or mTORC1 deactivation (Figs. 3, 4 and
Supplementary Fig. 3b). This suggested a discordant/distinct type
of preosteoclast metabolic quiescence, different from that of
T cells or hematopoietic stem cells30–32. We noted an in-between
state of arginine-restricted preosteoclasts between the M-CSF and
the M-CSF/RANKL signature (Fig. 3b), raising the possibility that
arginine depletion resulted in a ‘poised’ preosteoclast state that
was associated with a transient reversible osteoclastogenesis-
block. Indeed, osteoclast formation could be restarted even after
prolonged arginine starvation by arginine resupplementation and
even exhibited a tendency towards being increased relative to
controls (Supplementary Fig. 3c, d). Notably, the Arg-Starvation-
mediated inhibition of polykaryons was restored by arginino-
succinate and citrulline supplementation, but not by ornithine
and proline, indicating that select arginine precursor metabolites
bypass the dependence of arginine for RANKL signalling
(Fig. 6a). α-Ketoglutarate was not able to rescue arginine absence
(Supplementary Fig. 3e), suggesting that arginine scarcity could
not be compensated by direct TCA cycle refuelling but only by
AA derivatives. Together, dynamic metabolic adaptation to
environmental arginine deﬁciency sustains cellular ﬁtness until
intermediates are re-supplied and RANKL-dependent cellular
differentiation programs continued. In line with this ﬁnding,
in vivo recArg1 administration hindered but did not completely
abolish osteoclastogenesis, suggesting that arginine intermediates
can compensate for arginine scarcity in vivo (Fig. 1).
To evaluate whether other AAs were essential for RANKL
cellular programming, we next cultured preosteoclasts in media
selectively devoid of AAs and demonstrated commonalities in
metabolic blockage during osteoclastogenesis to a nutrient-
limited environment, especially regarding essential AAs (Fig. 6b,
Supplementary Fig. 8, Supplementary Table 1). As α-ketoiso-
caproate, ketoisoleucine and phenylpyruvate are intermediates of
the osteoclastogenesis essential AAs leucine, isoleucine and
phenylalanine, respectively, and can enter the TCA cycle
eventually via acetyl-CoA33, we next evaluated their compensa-
tory potential for the aforementioned AAs. In line with TCA/urea
cycle intermediates citrulline and argininosuccinate compensat-
ing for arginine deﬁciency (Fig. 6a), non-proteogenic metabolites
α-ketoisocaproate, ketoisoleucine and phenylpyruvate could
rescue defects in osteoclastogenesis that occurred in the absence
of their related AA (Fig. 6c). Therefore, these data suggest that
osteoclasts can adjust to the absence of environmental AAs by
utilizing their respective precursors or intermediates for success-
ful osteoclastogenesis.
IL-4 MGCs and osteoclasts share arginine requirements. Not-
ing that mononuclear innate immune cell in vitro differentiation
efﬁciency is independent of arginine absence (Supplementary
Fig. 4) and that RANKL induces giant cell formation, we next
examined whether the concept of arginine reliance holds true for
other MGCs. IL-4 induces myeloid cell multinucleation34,
resulting in MGCs that are distinct from osteoclasts but share
common characteristics35. Strikingly, extracellular arginine
removal using recArg1 prevented IL-4-generated MGCs (Fig. 7a).
Identical to the unremarkable requirements of intracellular ARG1
deﬁciency for RANKL-induced osteoclastogenesis, IL-4 robustly
induced MGCs in the absence of Arg1 (Fig. 7b). Using RT-PCR,
we conﬁrmed the previously observed effect of recArg1 on the
expression of select RANKL-modulated metabolic enzymes Pck2
and Sdhd (Figs. 5g, 7c). RANKL- or IL-4-dependent regulation of
Sdhd was further associated with increased expression of the
MGC signature gene Dcstamp. Notably, recArg1 treatment
exhibited identical effects on both enzymes in both cell types,
inducing Pck2 and downregulating Sdhd (Fig. 7c). Further, argi-
nine starvation abolished IL-4-induced MGC formation and this
was compensated by the same urea cycle intermediates in MGCs
as in osteoclasts (Figs. 6a and 7d, e) and associated with
improved OXPHOS (Fig. 7f).
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Discussion
Formation of MGCs such as osteoclasts is complex with previous
studies identifying a range of essential molecules, ranging from
surface receptors such as RANK to co-stimulatory molecules and
transcription factors2,16,35. Here, we demonstrate that in addition to
those factors, the extracellular availability of the AA arginine is
critical for RANKL and IL-4 induced differentiation of myeloid
precursor cells. While previous studies highlighted an importance
for cellular ARG1 in negatively regulating osteoclastogenesis36, here
we demonstrate that extracellular arginine is essential for RANKL-
induced metabolism. We found extracellular arginine presence is
critical for RANKL to elicit cellular programs and metabolic
changes, especially related to cellular respiration. Arginine with-
drawal during RANKL signalling was intrinsically linked to
downregulation of TCA cycle enzymes and metabolites. Metabolic
tracing experiments further conﬁrmed that a dysregulated TCA
cycle under arginine withdrawal occurred, associated with malate
accumulation derived from labelled aspartate. These changes
occurred early during osteoclastogenesis and preceded arginine-
dependent dampening of RANKL-induced bursts in cellular
respiration. Together, we demonstrate that in preosteoclasts extra-
cellular arginine presence is required for efﬁcient TCA function in
response to RANKL stimulation. Akin to osteoclasts, IL-4 induces
the formation of MGCs34. These cell types displayed clear simila-
rities in arginine-dependent oxidative metabolism, strengthening
the notion of arginine requirements to meet MGC energy demands.
Equivalent to osteoclasts, IL-4 MGCs were able to form by utilizing
arginine precursors to adapt to arginine scarcity. In contrast to
MGC differentiation, the presence of arginine was not required for
the terminal differentiation of other myeloid cells, such as bone-
marrow-derived macrophages or dendritic cells, suggesting speci-
ﬁcity for polykaryon formation.
Interestingly, mTOR is a central metabolic integrator, whose
role in osteoclastogenesis remains controversial37,38. Importantly,
although numerous studies in transformed cells suggested abso-
lute extracellular arginine requirements for mTOR activation18,
our data indicate that arginine is not required to sustain mTOR
signalling during RANKL-dependent osteoclastogenesis. Indeed,
upon arginine deprivation, we did not observe a reduction in
translation rates or diminished glycolysis, but rather a type of
preosteoclast metabolic quiescence associated with cell cycle
arrest and distinct to that previously described in other cell types
such as hematopoietic stem cells31. The effects of arginine
deprivation on osteoclastogenesis were fully reversible upon
arginine resupplementation and independent of increases in
recArg1 degradation products, such as ornithine and urea.
Notably, arginine absence could be compensated by its precursors
citrulline and argininosuccinate, suggesting requirements of a
functioning arginine recycling machinery during osteoclast
development.
Although our data demonstrate the crucial role of extracellular
arginine in osteoclastogenesis, absence of other AAs phenocopied
the blocks observed under arginine absence. Thus, osteoclasts
most likely couple extracellular AA amounts to their develop-
mental program, as scarcity in single essential AAs could be
compensated by osteoclast intrinsic re-synthesis through sup-
plementation of its derivatives or precursors. While here we
established TCA cycle dysregulation upon arginine withdrawal,
we cannot be certain if this is true for the remaining osteoclas-
togenesis essential AAs identiﬁed in this study. Nonetheless, given
osteoclastogenesis is an energy demanding process, it is plausible
that similar mechanisms of energy shifts under AA starvation are
in place as observed under arginine withdrawal. A plausible






























































































Fig. 6 Intermediates or precursors of amino acids including arginine can compensate for amino acid absence in osteoclastogenesis. a Urea cycle
metabolites can/cannot rescue arginine requirements in osteoclastogenesis in Arg-Free media (n= 4). b Schematic demonstrating which amino acids
are essential (white) versus non-essential (pink) for osteoclastogenesis. Star relates to TRAP-positivity with decreased occurrence of MGCs (n= 4).
c Immediate intermediates of leucine, isoleucine and phenylalanine degradation compensate for the lack of these amino acids and rescue
osteoclastogenesis. Representative TRAP stainings are shown (n= 4). aKIC alpha-ketoisocaproate, Ile isoleucine, KIle ketoisoleucine, Leu leucine,
Phe phenylalanine, PP phenylpyruvate. Scale bar represents 200 µm. Data are mean ± SEM. Source data are provided as a Source Data ﬁle.
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‘poised’ state of osteoclastogenesis is that osteoclast progenitors
‘integrate’ the lack of a key AA(s), which then triggers a pathway
that causes a selective block in the TCA cycle. For example, AA-
starved osteoclast progenitors could induce the downregulation
or degradation of key central metabolic enzymes, linking the
pathways. In this model, the effects of low AAs would be rapidly
reversible upon AA restoration and osteoclast development could
proceed, as we observed. Several examples of such reversible
metabolite signalling are known, including oxygen and iron
sensing39,40. Clearly, such an ‘information transfer system’ would
need to be independent from the mTOR and GCN2 pathways as
we found. Nevertheless, a ‘sensor’ must integrate information
from all the AAs described herein that block osteoclastogenesis,
or individual sensors for each AA may exist. However, such a
model needs to also account for the ‘rescue’ effect of each AA
precursor such as citrulline. Ultimately, we propose that AA
presence is required to sustain oxidative metabolism, which is
essential for multinucleation, and that this process may involve
yet to be discovered metabolic regulatory pathways. Together, our
data establish how availability of environmental AAs, especially
arginine, control polykaryon developmental programs and
metabolism. They further imply therapeutic strategies for argi-
nine depletion in MGC-mediated diseases.
Methods
Human studies. Human patient serum was used freshly for osteoclastogenesis
assays or processed and stored until analysis according to standard operating
procedures by the MedUni Wien Biobank, a central facility included in a certiﬁed
quality management system41. All study subjects provided informed consent. This
study was approved by the local ethics committee of the Medical University Vienna
(EK #559/2005). Arginine and ARG1 levels were assessed using ELISA (Arginine:
Immundiagnostik AG #K7733; human ARG1: Antibody Online Gmbh
#ABIN1113579).
Animals and arthritis models. Female wildtype animals (C57BL/6J, RRID:
IMSR_JAX:000664 and DBA/1J, RRID: IMSR_JAX:000670) used for in vivo
arthritis models were purchased from Charles River Laboratories. Serum-transfer


















































































































































































































































Fig. 7 Osteoclasts and IL-4-induced multinucleated giant cells (MGCs) share mechanisms of metabolic adaptation in nutrient scarcity.
a Representative H&E stainings of MGCs ± recArg1. b Representative H&E stainings of MGCs from Arg1Tie/+ and WT littermate controls. c qRT-PCR of
Pck2, Sdhd and Dcstamp in IL-4- (M-CSF+ IL-4) and RANKL (M-CSF+ RANKL)-induced MGCs ± recArg1. All data correspond to day 7, # corresponds to P
= 0.01 assessed by t-test (n= 4). d, e Representative H&E stainings (d) and quantiﬁcations (e) of nuclei per cell of IL-4-generated MGCs in the absence of
arginine (Arg-Free Media), re-supplemented with arginine, citrulline or argininosuccinate. Data represent cells counted in 50 random frames (n= 50). f IL-
4-induced MGC oxygen consumption rate (OCR) in the absence of arginine (Arg-Free Media), re-supplemented with arginine, citrulline and
argininosuccinate. Signiﬁcance was calculated by unpaired t-test between area under the curve (AUC) of indicated conditions (Arg-Free n= 10, arginine
n= 12, citrulline n= 11, argininosuccinate n= 11). Data are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA Tukey post-
hoc test and t-test (c), one-way ANOVA post-hoc pairwise comparisons with Bonferroni correction (e) and two-way ANOVA post Sidak’s multiple
comparisons test (f). Scale bar represents 200 µm (10×), 50 µm (40×) (a, d) and 200 µm (RANKL) and 100 µm (IL-4) (b). Source data are provided as a
Source Data ﬁle.
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day 0 and day 2 in C57BL/6J and animals were harvested post 13 days treatment42.
Human tumour necrosis factor (hTNFTg/+, RRID: MGI:3053718) transgenic ani-
mals were identiﬁed from tail tissue PCR using hTNFTg primers (5′-TACCC
CCTCCTTCAGACACC-3′ and 5′-GCCCTTCATAATATCCCCCA-3′) and were
used for experiments at 5–6 weeks of age. Mice were harvested after 5 weeks of
treatment. Female wildtypes (DBA/1J) were immunized subcutaneously with 50 μg
of chicken type II collagen (Sigma‐Aldrich #C9301) in 50 μl of H2O, emulsiﬁed in
50 μl of Freund’s complete adjuvant (Sigma‐Aldrich #F5881) that was enriched
with 10 μg/ml Mycobacterium tuberculosis (Difco/BD Biosciences #H37Ra), on day
1 and day 21. Mice were harvested after 8 weeks of treatment. Treatment regimen
comprised a dose of 50 mg/kg recArg1 or NaCl administered intra-peritoneally
twice weekly, starting 1 day before disease induction or at 5–6 weeks of age
regarding hTNFTg/+ mice. hTNFTg/+ mice were a kind gift of the George Kollias13.
Arginine levels were assessed using metabolomics or via ELISA (see below). Mouse
TNFSF11/RANKL (Boster #EK0843) and mouse TNFRSF11B/osteoprotegerin
(abcam #ab203365) serum levels were measured using ELISA. All animal proce-
dures were approved by the local ethics committee of the Medical University
Vienna (BMWFW-66.009/0013-V/3b/2019 and BMWFW-66.009/0227-WF/V/3b/
2017) and were conducted in strict accordance with Austrian law.
Clinical assessment of murine arthritis. Clinical signs of arthritis are described
by a well-established semi-quantitative double-blind score system43. Swelling per
paw was recorded: 0 to 3 (0= no swelling; 1=mild swelling of toes/ankle; 2=
moderate swelling of toes/ankle; 3= severe swelling of toes/ankle). Grip strength
per paw was assessed on a wire mesh: 0 to 3 (0= normal grip strength; 1=mildly
reduced grip strength; 2=moderately reduced grip strength; 3= severely reduced
grip strength). Total score was calculated by combining scores of swelling and grip
strength of all four paws. Inclusion criteria for the hTNFTg/+ control group was a
combined clinical score of over 5, at 10 weeks of age.
Histological analyses. Hind paws were ﬁxed in 4.5% formalin for 6 h and then
decalciﬁed in 14% pH 7.2 EDTA/ammonium hydroxide buffer (Sigma #318604) at
4 °C until bones were pliable. Afterwards, 2 μm decalciﬁed parafﬁn-embedded
sections were prepared and stained with haematoxylin and eosin (H&E) and TRAP
(#387A, Leukocyte Phosphatase Staining Kit, Sigma Diagnostics). In brief, slides
were stained for 10 min with 1:5 diluted Meyer’s hemalum (Merck #1.09249.0500),
rinsed with distilled water, differentiated in 1% HCl ethanol and rinsed again for
10 min. Afterwards, slides were stained in eosin working solution (300 ml 1% Eosin
Sigma #318906, 600 ml distilled water, 0.1 ml acetic acid 100%) for 15 min. Slides
were then rinsed with distilled water, 96% ethanol, n-Butyl-acetate and mounted.
Regarding TRAP staining, slides were stained for 1 h at 37 °C with the TRAP
staining solution (250 µl naphthol AS-BI phosphoric acid, 1000 µl acetate solution,
500 µl tartrate solution, 45 ml distilled water; Sigma-Aldrich #387A) protected from
light. Afterwards, slides were developed for 2 min at 37 °C with a mix of 250 µl of
Fast garnet GBC base solution and 250 µl of sodium nitrite solution. Nuclei were
stained with Meyer’s hemalum as described above and slides mounted in Aquatex
(Merck #108562). Sections were analysed using an Axioskop 2 microscope (Carl
Zeiss MicroImaging) and Osteomeasure Analysis System (OsteoMetrics) to
quantify the areas of inﬂammation, erosion and osteoclast numbers.
Ctsk in vivo imaging. Cat K 680 FAST (Perkin Elmer #NEV11000) was recon-
stituted and 100 µl per animal injected intravenously according to the manu-
facturer’s guidelines. Ctsk intensity (Avg Radiant Efﬁciency) was determined by
IVIS® Lumina Series III (Perkin Elmer) 24 h post injection.
In vitro restimulation of spleen cells with collagen. Spleen cells were harvested,
passed through a nylon mesh, and cultured at a density of 2 × 106 cells/ml in RPMI
1640 (L-glutamine, 10% FCS, penicillin/streptomycin, β2-mercaptoethanol) and
stimulated with 100 μg/ml of chicken type II collagen (Sigma-Aldrich #C9301) for
72 h. During the last 18 h of culture, cells were incubated with 1 μCi/well of 3H-
thymidine, to quantify proliferation using a scintillation counter (Beckman).
Osteoclastogenesis and staining. Wildtype animals (C57BL/6J) used as bone
marrow donors were bred at the Medical University Vienna. Hematopoietic stem
cells of the bone marrow were isolated and cultured in complete MEMα (Gibco
#32561037) containing 5% Pen-Strep (Gibco #15140122) and 10% foetal calf serum
(FCS, Gibco #10082147) supplemented with 100 ng/ml M-CSF (R&D Systems
#416). After 3 days, cells were harvested, plated and cultured in Full-MEMα
supplemented with 30 ng/ml M-CSF and/or 50 ng/ml RANKL (R&D Systems
#462) for another 3–4 days including one medium change on day 6. Osteoclasts
were deﬁned as multinucleated cells (≥3 nuclei) with TRAP positivity (Sigma-
Aldrich #387A). RecArg1 was used in vitro at 1 µg/ml starting at day 3 of osteo-
clastogenesis, unless otherwise stated. Arg-Free and AA-free media (both Gibco
custom MEMα based on #32561037) was supplemented with dialyzed FCS (Gibco
#26400036) and AAs and used starting day 3 of osteoclastogenesis. Preosteoclasts
in tryptophan and cysteine-free medium were cultured in 5% dialyzed FCS to
control for serum-bound AAs44 (Supplementary Table 1). 2-(diﬂuoromethyl)
ornithine (DFMO) was a kind gift from the Woster Lab (MUSC) and used at a
concentration of 2.5 mM. Tsc2ﬂ/ﬂ and Rictorﬂ/ﬂ LysMcre+/− have previously been
described45,46. Eif2ak4−/− (B6.129S6-Eif2ak4tm1.2Dron/J) and Arg1ﬂ/ﬂTie2+/− bone
marrow was provided by the Murray Lab17,44. Ddit3−/− (B6.129S(Cg)-
Ddit3tm2.1Dron/J) animals were acquired from the Jackson Laboratories. Slc38a9−/−
(unpublished) bone marrow was a kind gift from the Surperti-Furga Lab20. Human
monocytes were isolated from whole blood using Histopaque-1077 and
Histopaque-1119 (Sigma #10771 and #11191) and CD14+ cells sorted using CD14-
PerCP-Cy5.5 (eBioscience #45-0149, 61D3). Monocytes were resuspended in
complete MEMα medium (5% Pen-Strep, 10% FCS) with 25 ng/ml M-CSF. After
overnight incubation with M-CSF, human RANKL (R&D Systems #390) was added
at 25 ng/ml for another 3–4 days including one medium change on day 6.
Osteoclasts were deﬁned as multinucleated cells (≥3 nuclei) with TRAP positivity.
Blood from healthy donors included in this study was provided by the Biobank for
patients with rheumatic diseases and were approved by the Clinical Research Ethics
Committees of the Medical University Vienna (EK Nr. 559/2005). An informed
consent was obtained from all subjects.
Giant cell formation and staining. Bone marrow cells were cultured for 3 days in
Full-MEMα containing 15% v/v L929-supernatant on 6-well non-treated plastic
plates. Adherent macrophages were detached using 1× PBS (10 mM EDTA). Cells
were plated in Permanox® 8-well chamber slides in Full-MEMα containing 15 ng/
ml IL-4 (R&D Systems #404) and described stimuli for another 3 days, after which
the medium was renewed. Three days later, cells were stained using H&E. H&E-
stained slides were analysed using an Axioskop 2 microscope (Carl Zeiss Micro-
Imaging). For nuclei counts, cells were washed with PBS and stained (0.5% PFA,
0.1% Triton X-100, 0.1% Hoechst 33342, 0.15% Phalloidin AlexaFluor488 in 1×
PBS) for 20 min in the dark. Afterwards, cells were washed again and kept in PBS
for imaging. Twenty-ﬁve random images per well were taken and analysed using
Cell Proﬁler47.
Macrophage and dendritic cell differentiation. Macrophage or dendritic cells
were differentiated from hematopoietic stem cells cultured in presence of 30 ng/ml
M-CSF (macrophages) or 20 ng/ml granulocyte macrophage colony-stimulating
factor (GM-CSF, R&D #215 DCs) and 5 ng/ml IL-4 (dendritic cells), with complete
medium changes on days 3 and 6. On day 7, cells were harvested and analysed
using ﬂow cytometry.
Quantitative PCR. Total RNA was extracted from paws and cells using RNA
isolation kits (QIAGEN RNeasy; Peqlab Trifast). Reverse-transcription was per-
formed using commercially available kits (Applied Biosystems). SYBR Green
Supermix (Bio-Rad Laboratories) was used for the qPCR reaction. Postampliﬁca-
tion melting curve analysis and water controls were included to ensure absence of
primer dimers. To obtain sample-speciﬁc ΔCt values, normalization to hypox-
anthine phosphoribosyltransferase 1 (Hprt) within each sample was performed.
Data are shown as fold change, where 2−ΔΔCt values were calculated (ΔΔCt= ΔCt
treatment− ΔCt control). RT-PCR was performed using the following primers:
Hprt: 5′-CGCAGTCCCAGCGTCGTG-3′ and 5′-CCATCTCCTTCATGACATC
TCGAG-3′; Nfatc1: 5′-GACAGACATCGGGAGGAAGA-3′ and 5′-AGCCTTCT
CCACGAAAATGA-3′; Ctsk: 5′-GGAAGAAGACTCACCAGAAGC-3′ and 5′-GT
CATATAGCCGCCTCCACAG-3′; Acp5: 5′-ACAGCCCCCACTCCCACCCT-3′
and 5′-TCAGGGTCTGGGTCTCCTTGG-3′; Tnf: 5′-CCACCACGCTCTTCTG
TCTAC-3′ and 5′-AGGGTCTGGGCCATAGAACT-3′; Fos: 5′-AGCCCAGACCT
GCAGTGGCT-3′ and 5′-GCGCTCTGCCTCCTGACACG-3′; Mt-ND2: 5′-AGGG
ATCCCACTGCACATAG-3′ and 5′-5CTCCTCATGCCCCTATGAAA-3′; Arg1:
5′-GGAAAGCCAATGAAGAGCTG-3′ and 5′-GCTTCCAACTGCCAGACTGT-
3′; Dcstamp: 5′-TCCTCCATGAACAAACAGTTCCAA-3′ and 5′-AGACGTGGTT
TAGGAATGCAGCTC-3′; Sdhd: 5′-TGGTCAGACCCGCTTATGTG-3′ and 5′-
GGTCCAGTGGAGAGATGCAG-3′; Pck2: 5′-TGCCAGGCTGGAAAGTGGAG
TGT-3′ and 5′-GCAACCCCAAAGAAGCCGTTCTCA-3′.
Western blot. Cells were washed with ice-cold PBS, scraped and centrifuged at
400 × g for 5 min at 4 °C and the resulting pellet was lysed with lysis buffer
((20 mM Hepes pH 7.4, 400 mM NaCl, 25% v/v glycerol, 1 mM EDTA, 0.5 mM
NaF, 0.5 mM Na3VO4, 0.5 mM DTT) supplemented with Triton-X, PMSF, PIM
and RPI shortly before use). The homogenate was cleared by centrifugation at 4 °C
for 10 min at 16,000 × g and the supernatant containing the protein fraction
recovered. Protein concentration in the supernatant was determined using the
Pierce BCA Protein Assay Kit (Thermo Fisher Scientiﬁc #23225). A total of 15 μg of
proteins were resolved by SDS-PAGE and transferred to PVDF membranes (GE
Healthcare #10600023). Membranes were blocked with 1% Western Blocking
Reagent (Roche #11096176001) and incubated with primary antibodies at 4 °C
overnight. The following antibodies were used: p-pS6K T389 (Cell Signaling #9234,
108D2, 1:1000), 4EBP1 (Cell Signaling #9452, 1:500), p-mTOR Ser2448 (Cell
Signaling #5536, D9C2, 1:1000), total S6K (Cell Signaling #2708, 49D7, 1:1000),
Grb2 (BD #610112, 81, 1:1000), p-eIF2a XP Ser51 (Cell Signaling #3398, D9G8,
1:1000), p-4EBP1 Thr37/46 (Cell Signaling #2855, 236B4, 1:500), Tubulin (Cell
Signaling #3873, DM1A, 1:1000), ARG1 (Merck #ABS535, 1:000) and Actin (Sigma
Aldrich #A2066, 1:1000). Incubated membranes were washed three times for 5 min
with 0.5% Western Blocking Reagent and probed with the appropriate anti-igG-
horseradish peroxidase-linked (HRP) secondary antibody (GE Healthcare #NA934,
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anti-rabbit IgG, 1:20,000; #NA931, anti-mouse IgG, 1:20,000; Promega #G135A,
anti-chicken IgY, 1:20,000). Antigen-speciﬁc binding of antibodies was detected
with SuperSignal West Femto and Pico Kits (Thermo Scientiﬁc #34095 and
#34577).
Metabolism assays. OCR and extracellular acidiﬁcation rate (ECAR) measure-
ments were performed on a Seahorse XFe96 Analyzer (Agilent) using the Seahorse
XF Cell Mito Stress test kit (Agilent #103015-100) according to the manufacturer’s
instructions. In brief, 150,000 preosteoclasts were seeded per well and treated with
respective stimuli. During the measurements, oligomycin (1 µM), carbonyl cya-
nide-p-triﬂuoromethoxyphenylhydrazone (FCCP, 1 µM) and rotenone/antimycin
A (500 nM) were subsequently injected. Raw data were analysed using Wave
Desktop Software (Agilent, version 2.6.1) and exported and graphed in GraphPad
Prism 8 (GraphPad Software).
Flow cytometry. Plated preosteoclasts were harvested in Accutase solution (Sigma
Aldrich #A6964) and later stained for DAPI (Biolegend #422801, 1:200), ﬁxable
viability dye (Invitrogen #65-0865-14, 1:2000), MitoTracker Green (Thermo Fisher
#M7514, 100 nM) and F4/80-BV421 (BioLegend #123131, BM8, 1:80) according to
the manufacturer’s instructions. Bone marrow dendritic cells and macrophages
were FC blocked with TruStain fcX (BioLegend #101320, 1:200) and surface stained
for CD45.2-APC (TONBO #20-0454, 104, 1:80), CD11c-APC-eF780 (eBioscience
#47-0114, N418, 1:50), CD11b-PeCy7 (eBioscience #25-0112, Clone M1/70, 1:400),
MHC Class II-PE (TONBO #50-5321, M5/114.15.2, 1:80) and F4/80-BV421. For
in vivo assessment of osteoclast precursors, mashed splenocytes were stained for
CD45.2-APC, F4/80-FITC (BioLegend #123108, BM8, 1:80), CD11b-PeCy7 and
GR-1-PE (Ly-6G/Ly-6C, BioLegend #108408, RB6-8C5, 1:80). Cells were acquired
and analysed using CytoFLEX S Flow Cytometry (Beckman Coulter), CytExpert
(Version 2.0) and FlowJo (Version 10, LLC) software. MFI represents mean
ﬂuorescence intensity for Fig. 4e.
Bioinformatics analysis. All bioinformatics analyses and visualizations have been
conducted using R version 3.5.1, ggplot2 3.1.0 and heatmaply 0.15.2 (ref. 48).
Network analysis relied on OmicsIntegrator 0.3.1 (ref. 49) version 1.0 of the python
implementation of Infomap50 and Cytoscape 3.6.1 (ref. 51). All the code and
software parameters used for this study are provided through Jupyter notebooks on
a Github repository.
Transcriptomics. Total RNA was prepared from 1 × 106 preosteoclasts using
TRIzol Reagent (Thermo Fisher Scientiﬁc, #15596026). A total of 200 ng of total
RNA was subsequently utilized for RNA-Seq library preparation by using TruSeq
SR RNA sample prep kit (Illumina, #FC-122–1001), following the manufacturer’s
protocol. The libraries were sequenced for 50 cycles (single read) with a HiSeq 2000
(Illumina). Raw sequencing data were processed with CASAVA 1.8.2 to generate
FastQ ﬁles. Sequence reads were mapped onto the mouse genome build mm9 using
TopHat 2.0 (ref. 52). From the RNA-Seq alignments ﬁles, read counts have been
obtained for mm9 using Rsubread’s featureCount53, with and without allowing
reads mapping multiple genes and counting overlapping reads for multiple genes.
The results were similar using both methods. For instance, the Jaccard coefﬁcient
was equal to 0.837 when looking at genes differentially expressed between RANKL
and RANKL/Arg-Depletion conditions with and without allowing for multi-
mapping reads. Therefore, of the 469 genes found to be differentially expressed
with or without read multimapping, 393 were common. The differential expression
analysis was thus ﬁrst based solely on counts obtained allowing multimapping
reads (Figs. 2b, 3b, c, 4g and Supplementary Fig. 2). Genes were ﬁltered to keep
only those with log(CPM+ 0.25) > 0 in at least three samples. Library sizes were
scaled, values were transformed and variance corrected in order to ﬁt a linear
model explaining the read abundances using the voom method54 before identifying
differentially expressed genes between conditions, with a log2 fold-change higher
than 1 for a false discovery rate (FDR) of 5% using limma55 and edgeR56. Hier-
archical clustering with complete linkage of the z-score-transformed expression
values for the 40 genes with highest difference between RANKL and RANKL/Arg-
Depletion segregated all samples by experimental conditions. The gene sets iden-
tiﬁed were tested for enrichment using the clusterProﬁler library57 for the different
levels of the Gene Ontology (GO)58,59 and KEGG60,61 in Mus musculus. Moreover,
genes were ﬁltered on membership to metabolism (mmu:09100) or KEGG path-
ways of interest (mmu00010, mmu00020, mmu00220, mmu00330) using the REST
API provided. Pairwise comparisons in expression levels between conditions were
assessed using a permutation test, with the null hypothesis that there were no
associations between the expression of any gene of the pathway and the conditions
compared. Samples were ranked on their expression level for each gene in the
pathway and the absolute difference between the sum of the ranks of the four
replicates in each condition were summed over all genes, deﬁning the test statistic.
The association between samples and conditions was randomized 12,000 times and
the same value computed, resulting in an empirical P-value by comparing the
observed statistic to the simulated distribution. These values were reported after
Bonferroni correction. The intersection of genes differentially expressed both with
and without counting multimapping reads was then used to generate robust gene
sets for the multi-omics integration analysis.
Proteomics. Cell pellets were lysed in 8 M urea, 10 mM HEPES (pH 8), 10 mM
DTT and sonicated at 4 °C for 15 min (level 5, Bioruptor, Diagenode). Alkylation of
reduced cysteines was performed in the dark for 30 min with 55 mM iodacetamide
(IAA) followed by a two-step proteolytic digestion. Samples were digested at
21–24 °C with LysC (1:50, w/w, Wako) for 3 h. Cell lysates were adjusted to 2M
Urea with 50 mM ammoniumbicarbonate and then both cell lysates and super-
natants were digested with trypsin (1:50, w/w, Promega) at 21–24 °C overnight.
The resulting peptide mixtures were acidiﬁed and loaded on C18 StageTips
(EmporeTM, IVA-Analysentechnik). Peptides were eluted with 80% acetonitrile
(ACN), dried using a SpeedVac centrifuge, and resuspended in 2% ACN, 0.1%
triﬂuoroacetic acid (TFA) and 0.5% acetic acid. Chemicals were purchased from
Sigma-Aldrich unless stated otherwise. For ultra-high pressure LC–MS, peptides
were separated on an EASY-nLC 1200 HPLC system (Thermo Fisher Scientiﬁc)
coupled online to the Q Exactive HF-X mass spectrometer via a nanoelectrospray
source (Thermo Fisher Scientiﬁc)62. Peptides were loaded in buffer A (0.5% formic
acid) on in house packed columns (75-μm inner diameter, 50 cm length and 1.9 μm
C18 particles from Dr. Maisch GmbH, Germany). Peptides were eluted with a
nonlinear 170-min gradient of 5–60% buffer B (80% ACN, 0.5% formic acid) at a
ﬂow rate of 300 nl/min and a column temperature of 55 °C. The Q Exactive HF was
operated in a data-dependent mode with a survey scan range of 300–1650m/z and
a resolution of 60,000–120,000 at m/z 200. Up to the ten most abundant isotope
patterns with a charge > 1 were isolated with a 1.4 Thomson (Th) isolation window
and subjected to higher-energy collisional dissociation (HCD) fragmentation at a
normalized collision energy of 27. Fragmentation spectra were acquired with a
resolution of 15,000 at m/z 200. Dynamic exclusion of sequenced peptides was set
to 30 s to reduce repeated peptide sequencing. Thresholds for ion injection time
and ion target values were set to 20 ms and 3E6 for the survey scans and 60 ms and
1E5 for the MS/MS scans, respectively. Data were acquired using the Xcalibur
software (Thermo Scientiﬁc). MaxQuant software (version 1.5.3.2) was used to
analyse MS raw ﬁles63. MS/MS spectra were searched against the human Uniprot
FASTA database (Version July 2015, 91645 entries) and a common contaminants
database (247 entries) by the Andromeda search engine64. Cysteine carbamido-
methylation was applied as ﬁxed and N-terminal acetylation, deamidation at NQ,
and methionine oxidation as variable modiﬁcations. Enzyme speciﬁcity was set to
trypsin with a maximum of 2 missed cleavages and a minimum peptide length of
7 AAs. An FDR of 1% was applied at the peptide and protein level. Peptide
identiﬁcation was performed with an allowed initial precursor mass deviation of up
to 7 ppm and an allowed fragment mass deviation of 20 ppm. Nonlinear retention
time alignment of all measured samples was performed in MaxQuant. Peptide
identiﬁcations were matched across all samples within a time window of 1 min of
the aligned retention times. A library for ‘match between runs’ in MaxQuant was
built from duplicate and additional single shot MS runs from MACS enriched cell
types. Protein identiﬁcation required at least 1 ‘razor peptide’ in MaxQuant. A
minimum ratio count of 1 was required for valid quantiﬁcation events via Max-
Quant’s Label Free Quantiﬁcation algorithm (MaxLFQ). Downstream bioinfor-
matic analysis was conducted in the Perseus environment65. Each quantiﬁed
protein was required to be identiﬁed in three out of four replicates of at least one
condition. Protein LFQ intensities were logarithmised to the base 2 and missing
values imputed from a random normal distribution centred on the detection limit.
Data were imported into Perseus, ﬁltered to keep only proteins where the coefﬁ-
cient of variation of overall abundance was greater than the coefﬁcients of variation
in every condition, to select for proteins that consistently vary between conditions
but not between replicates, and converted to z-scores. Average abundances among
different conditions were compared by a two-sided Student’s t-test (permutation-
based FDR= 0.05, s0= 0.05) and used to select proteins with differential abun-
dance between conditions. As in the transcriptomic analysis, hierarchical clustering
with complete linkage of the z-score-transformed data segregated the samples by
experimental conditions.
Network integrative analysis. OmicsIntegrator was used to integrate tran-
scriptomic and proteomic changes, by addressing the underlying molecular
mechanisms of the effects of recArg1 and the arginine-dependent effects of
RANKL49. This tool circumvents the low overlap between proteomic and tran-
scriptomic hits (Supplementary Fig. 6b), by inferring transcription factors likely to
explain the transcriptional changes and searching for minimal sets of connected
genes including these transcription factors and abundantly changed proteins. The
ﬁrst set of proteins and genes, describing the effect of recArg1, were deﬁned by
signiﬁcantly changed abundance or expression respectively between RANKL/Arg-
Rescue and RANKL/Arg-Depletion for proteomics data, and between RANKL and
RANKL/Arg-Depletion for transcriptomics data. The second set, describing the
arginine-dependent effect of RANKL, was deﬁned as the exclusive disjunction of
proteins or genes with changes in abundance or expression between RANKL-
positive and RANKL-negative conditions in the presence and absence of arginine.
By doing so, we selected for genes differentially expressed between M-CSF and
RANKL or M-CSF/Arg-Rescue and RANKL/Arg-Rescue but not between M-CSF/
Arg-Starvation and RANKL/Arg-Starvation, and proteins with different abundance
between M-CSF/Arg-Rescue and RANKL/Arg-Rescue but not between M-CSF/
Arg-Starvation and RANKL/Arg-Starvation. The protein interactions used were
mouse–mouse interactions from BioGRID Release 3.4.160 (ref. 66), weighted by
directness and experimental strength of the assay (Supplementary Table 2). The
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garnet tool was used to identify transcription factors explaining transcriptomic
variability, converted to up-to-date murine identiﬁers and integrated with hit
proteins via the Forest tool. The overlap between both resulting Steiner trees was
contextualized by randomly selecting 2000 connected subgraphs of matched size on
the BioGRID network and examining the corresponding shared nodes. Infomap
algorithm and its python implementation50 were used to cluster nodes into
modules (two-level clustering) with a scaling factor of the link ﬂows allowing a
limited number of communities (--markov-time 2.5), which were visualized with
the map generator67. Major network structures were identiﬁed according to coding
theory, by looking at which grouping of the nodes allows the minimal coding of
trajectories of random walks on the network (Supplementary Table 3). The
information ﬂow inside and between these groups therefore represents how tightly
connected nodes are inside and between these groups. The resulting communities
were analysed for enrichment in GO Biological processes.
Metabolomics and 13C6 arginine tracing. Cells were cultured for 24 h in the
presence of fully labelled arginine (13C6 arginine, Sigma Aldrich). Medium was
collected and 10 µl of 13C-glycerol (150 µl/ml) was added as internal standard. Cells
were scrapped, collected and frozen. Cell pellets were resuspended with 300 µl of
cold methanol/water (8:1, v/v) containing 13C-glycerol (5 µl/ml) as internal stan-
dard. Metabolites were extracted with three rounds of liquid N2 immersion and
sonication, followed by 1 h in ice before centrifugation at 22,800 × g (10min at
4 °C). Medium was collected and 10 µl of 13C-glycerol (150 µl/ml) was added as
internal standard. The medium samples were lyophilized and resuspended in 500 µl
of cold methanol/water (8:1, v/v). After vortexing, samples were left 1 h in ice and
centrifuged 10min at 22,800 × g (4 °C). Metabolite extraction of cells and medium
was split into two aliquots of 250 µl (cells) or 400 µl (medium) for gas
chromatography–MS (GC–MS), and 40 µl (both) for LC–MS analysis. For GC–MS
analysis, samples were dried under a stream of N2 gas and lyophilized before
chemical derivatization with 40 µl of methoxyamine in pyridine (30 µg/ml) for
45min at 60 °C. Samples were also silylated using 25 µl of N-methyl-N-tri-
methylsilyltriﬂuoroacetamide with 1% trimethylchlorosilane (Thermo Fisher Sci-
entiﬁc) for 30min at 60 °C to increase volatility of metabolites. A 7890A GC system
coupled to a 7000 QqQ mass spectrometer (Agilent Technologies) was used for
isotopologue determination. Derivatized samples were injected (1 µl) in the gas
chromatograph system with a split inlet equipped with a J&W Scientiﬁc HP-5ms
stationary phase column (30m × 0.25 mm i.d., 0.1 µm ﬁlm, Agilent Technologies).
Helium was used as a carrier gas. The temperature gradient was the following: from
70 to 150 °C at a heating rate of 5 °C/min, from 150 to 250 °C at 10 °C/min and
from 250 to 325 °C at 50 °C/min. Metabolites were ionized using positive chemical
ionization (CI) with isobutene as reagent gas. Mass spectral data on the 7000 QqQ
were acquired in scan mode monitoring selected ion clusters of the different
metabolites (Supplementary Table 4). For LC–MS analysis, samples were analysed
using an UHPLC system coupled to a 6490 QqQ mass spectrometer (Agilent
Technologies) to determine arginine. Cells and medium extracts were injected (5 µl
and 1 µl, respectively) and metabolites separated using an ACQUITY UPLC HSS T3
column (1.8 µm, 2.1 × 150mm, Waters). The mobile phases used for the separation
of the metabolites were A: water with 0.1% formic acid and B: ACN with 0.1%
formic acid. The chromatographic gradient was isocratic for 2 min at 100% A, and
from minute 2 to 3 decreased to 10% A. From minute 3 to 4, the percentage of A
raised again to 100% and ﬁnally the column was equilibrated at 100% A until 8 min.
Flow rate was 0.3 ml/min. The QqQ mass spectrometer worked in MRM mode
using the transitions 181→ 74 (CE:20V) and 181→ 121 (CE:8V) to determine
labelled Arg. The electrospray ionization source (ESI) worked in positive mode.
13C6 arginine and 13C4 aspartate tracings. Cells were cultured for 24 h in the
presence of fully labelled arginine (13C6 L-arginine, Cambridge Isotope Laboratories
#CLM-2265) and fully labelled aspartate (13C4 L-aspartic acid, Cambridge Isotope
Laboratories #CLM-1801). Cell extracts where centrifuged for 10 min at 5000 × g.
The supernatant was collected and dried using nitrogen evaporator. The samples
were reconstituted in 50 µl of methanol, centrifuged for 10 min at 1000 × g and
supernatant was used for LC–MS analysis. For AA tracing, a Vanquish UHPLC
system (Thermo Scientiﬁc) coupled to an Orbitrap Fusion Lumos (Thermo Sci-
entiﬁc) mass spectrometer was used for the LC–MS analysis. The chromatographic
separation for samples was carried out on an ACQUITY UPLC BEH Amide,
1.7 µm, 2.1 × 100 mm analytical column (Waters) equipped with a VanGuard: BEH
Amide, 2.1 × 5 mm pre-column (Waters). The column was maintained at a tem-
perature of 40 °C and 2 µl sample were injected per run. The mobile phase A was
0.15% formic acid (v/v) in water and mobile phase B was 0.15% formic acid (v/v) in
85% ACN (v/v) with 10 mM ammonium formate. The gradient elution with a ﬂow
rate 0.4 ml/min was performed with a total analysis time of 17 min. The mass
spectrometer was operated in a positive electrospray ionization mode: spray voltage
3.5 kV; sheath gas ﬂow rate 60 arb; auxiliary gas ﬂow rate 20 arb; capillary tem-
perature 285 °C. For the analysis a full MS scan mode with a scan range m/z
50–250, resolution 500,000; AGC target 2e5 and a maximum injection time 50 ms
was applied. The data processing was performed with the TraceFinder 4.1 software
(Thermo Scientiﬁc). For TCA cycle tracing, a Vanquish UHPLC system (Thermo
Scientiﬁc) coupled to an Orbitrap Fusion Lumos (Thermo Scientiﬁc) mass spec-
trometer was used for the LC–MS analysis. The chromatographic separation for
samples was carried out on an ACQUITY HSS T3, 1.8 µm, 2.1 × 100 mm analytical
column (Waters) equipped with a VanGuard HSS T3, 2.1 × 5 mm pre-column
(Waters). The column was maintained at a temperature of 40 °C and 2 µl of sample
was injected per run. The mobile phase A was 0.1% formic acid (v/v) in water and
mobile phase B was 0.1% formic acid (v/v) in methanol. The gradient elution with a
ﬂow rate 0.5 ml/min was performed with a total analysis time of 10 min. The mass
spectrometer was operated both in positive and negative electrospray ionization
mode: spray voltage for positive mode 3.5 kV and 3.0 kV for negative mode; sheath
gas ﬂow rate 60 arb; auxillary gas ﬂow rate 20 arb; capillary temperature 285 °C. For
the analysis a full MS scan mode with a scan range m/z 80–400, resolution 500,000;
AGC target 2e5 and a maximum injection time 50 ms was applied. The data
processing was performed with the TraceFinder 4.1 software (Thermo Scientiﬁc).
Serum metabolomics. Serum concentrations of arginine were assessed using an
arginine ELISA Kit (#K 207733, IDK). For serum samples, 10 µl of sample was
placed on a 96-well hydrophobic ﬁlter plate and mixed with 10 µl of an isotopically
labelled internal standard mixture. A total of 300 µl of methanol was added and the
plate was shaken for 20 min at 450 rpm. Afterwards, the sample extract was col-
lected in a 96-well plate by centrifuging the ﬁlter plate for 5 min at 500 × g. The
sample extracts were used for LC–MS analysis. A Vanquish UHPLC system
(Thermo Scientiﬁc) coupled with an Orbitrap Q Exactive (Thermo Scientiﬁc) mass
spectrometer was used for the LC–MS analysis. The chromatographic separation
for samples was carried out on an ACQUITY UPLC BEH Amide, 1.7 µm, 2.1 × 100
mm analytical column (Waters) equipped with a VanGuard: BEH C18, 2.1 × 5 mm
pre-column (Waters). The column was maintained at a temperature of 40 °C and
the sample injection volume was 2 µl. The mobile phase A was 0.15% formic acid
(v/v) in water and mobile phase B was 0.15% formic acid (v/v) in 85% ACN (v/v)
with 10 mM ammonium formate. The gradient elution with a ﬂow rate 0.4 ml/min
was performed with a total analysis time of 17 min. The Orbitrap Q Exactive
(Thermo Scientiﬁc) mass spectrometer was operated in an electrospray ionization
positive mode, spray voltage 3.5 kV, aux gas heater temperature 400 °C, capillary
temperature 350 °C, aux gas ﬂow rate 12. The metabolites of interest were analysed
using a full MS scan mode, scan range m/z 50–400, resolution 35,000, AGC target
1e6, maximum IT 50ms. The Trace Finder 4.1 software (Thermo Scientiﬁc) was
used for the data processing. Seven-point linear calibration curves with internal
standardization and 1/x weighing were constructed for the quantiﬁcation of
metabolites.
Image processing. Images were cropped and processed using Adobe Photoshop
CS6, adjusting brightness and contrast. Original uncropped Western Blot images
are provided in the source data ﬁle.
Statistics. Statistical analysis was performed using a two-tailed t-test for two
groups, an ordinary one-way ANOVA followed by Bonferroni’s multiple com-
parisons test or Tukey post-hoc test for multiple groups and a two-way ANOVA
followed by Bonferroni’s multiple comparisons test for curve analysis, unless
otherwise stated. Statistical outliers for patient data in Fig. 1 have been excluded
based on alpha= 0.05 on Prism 8 software (GraphPad, La Jolla, CA). In vitro data
are representative of at least two repeats, while transcriptomics, proteomics and
metabolomics correspond to biological replicates. Statistical signiﬁcance is indi-
cated by *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001. All error bars
indicate ±SEM.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA-Seq data have been deposited in Gene Expression Omnibus (GEO) under accession
number GSE125101. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE68 partner repository with the dataset
identiﬁer PXD012405. The source data underlying Figs. 1–2 and 4–7 and Supplementary
Figs. 1–4 and 7 are provided as a Source Data ﬁle or available from the corresponding
authors upon reasonable request.
Code availability
All code used in the proteomics and transcriptomics differential analyses and subsequent
integration is available on GitHub (https://doi.org/10.5281/zenodo.2541644).
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